RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter ended June 30, 2004
Currency: Indian Rupees (Rs.) with U.S. Dollar (US$) convenience translation at Rs. 45.99 = US$1.00.

DRL is an Indian pharmaceutical company engaged in the manufacture and sale of formulations, active pharmaceutical ingredients (APIs), generics, and drug discovery. The financial statements are prepared in accordance with U.S. GAAP.

Key Financial Metrics

Margins: Gross margin decreased to 51.4% (from 55.1% in Q2 2003). Net income margin dropped to 3.4% (from 16.5%).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 6.2% to Rs. 5.11 billion, driven by growth in the API segment (+17.3%) and international formulations (+27.7%). This offset a significant decline in the Generics segment (-32.2%).
• Profitability Decline: Net income plummeted 78% to Rs. 173.4 million. Operating income collapsed from Rs. 842.1 million to Rs. 43.8 million.
• Foreign Exchange Impact: A significant foreign exchange loss of Rs. 322.7 million was recorded (compared to a gain of Rs. 78.2 million in the prior year), primarily due to the depreciation of the Indian rupee against the U.S. dollar and marking-to-market of forward contracts.
• Expense Increases: R&D expenses surged 61.2% to Rs. 525.4 million due to increased clinical trial expenditures. SG&A expenses rose 12.4%.
• Debt Levels: Short-term borrowings from banks increased dramatically from Rs. 320.6 million to Rs. 2.34 billion to fund working capital and investments.

Guidance, Outlook, and Risks

Management Commentary & Outlook

• Generics Segment: Management anticipates continued significant competition in the U.S. generics market, particularly for key products like fluoxetine and tizanidine. Success depends on the launch of new products and the outcome of patent litigation (34 ANDAs pending).
• API Segment: Sales of Ramipril in Europe are expected to stabilize or decline in fiscal 2005 following the initial launch surge.
• Drug Discovery: The company is increasing investment in clinical development of new chemical entities (NCEs), with DRF 1042 in Phase II trials in India and DRF 10945 completing Phase I in Canada.
• Recent Developments: Novo Nordisk suspended clinical trials for two licensed molecules (ragaglitazar and balaglitazone) in October 2004. The accounting treatment for unamortized upfront fees related to these compounds is under evaluation.

Risks and Contingencies

• Litigation (Norfloxacin): The Andhra Pradesh High Court dismissed DRL's appeal regarding price controls on Norfloxacin. DRL has filed a review petition and plans to appeal to the Supreme Court. A provision of Rs. 183.6 million was made in fiscal 2004, with an additional Rs. 5.5 million in Q2 2004. Unsuccessful litigation could require remitting excess sale proceeds to the government.
• Patent Law Changes: India is implementing product patents starting January 1, 2005, which may restrict the launch of new products and impact the generics business.
• Environmental Liability: Pending litigation regarding environmental compensation for farmers in the Patancheru area; additional liability is considered remote but possible.

Investor Verification Checklist

• FX Sensitivity: Verify the impact of the Indian Rupee's volatility on future earnings, given the significant foreign exchange loss in Q2 2004.
• Generics Pipeline: Monitor the status of the 34 pending ANDAs and the outcome of patent challenges, as these are critical for the recovery of the Generics segment.
• Novartis License Fees: Confirm the final accounting treatment of the Rs. 235.6 million license fee recognized in Q2 2004 upon the expiration of the Novartis agreement.
• Debt Servicing: Assess the sustainability of the increased short-term debt (Rs. 2.34 billion) and the company's ability to service interest at ~10.5%.
• Regulatory Risks: Track the progress of the Norfloxacin price control litigation in the Supreme Court of India.